Lee Dong-Hee, Choi Seunghyun, Park Yoon, Jin Hyung-Seung
Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
Pharmaceuticals (Basel). 2021 Oct 17;14(10):1053. doi: 10.3390/ph14101053.
The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. Interestingly, some MUC proteins are aberrantly expressed in cancer cells and are involved in cancer development and progression, including cell growth, proliferation, the inhibition of apoptosis, chemoresistance, metabolic reprogramming, and immune evasion. With their unique biological and structural features, MUC proteins have been considered promising therapeutic targets and also biomarkers for human cancer. In this review, we discuss the biological roles of the transmembrane mucins MUC1 and MUC16 in the context of hallmarks of cancer and current efforts to develop MUC1- and MUC16-targeted therapies.
粘蛋白(MUC)家族是一组高度糖基化的大分子,在哺乳动物上皮细胞中大量表达。MUC蛋白有助于黏液屏障的形成,因此具有抗感染的保护功能。有趣的是,一些MUC蛋白在癌细胞中异常表达,并参与癌症的发生和发展,包括细胞生长、增殖、细胞凋亡抑制、化疗耐药、代谢重编程和免疫逃逸。由于其独特的生物学和结构特征,MUC蛋白被认为是有前景的治疗靶点以及人类癌症的生物标志物。在这篇综述中,我们在癌症特征的背景下讨论跨膜粘蛋白MUC1和MUC16的生物学作用,以及目前开发针对MUC1和MUC16疗法的努力。